SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jaybe who wrote (3250)2/26/2014 2:03:36 PM
From: Biomaven  Read Replies (1) of 4474
 
>>I think HB's pan-inhibitor means targeting the kinase and known mutations as well as potentially alternate activated pathways such as PI3K

Unclear to me because they used the term "pan-inhibitor" for pona to mean it inhibits all (single) mutations of the target. Nothing about alternate pathways there.

I wouldn't call RON clinically validated at this point at all, and MET inhibitors still have considerable doubt associated with them.

Something like a pan-KIT inhibitor would fit their descriptions better. There are a class of mutations that none of the existing drugs (including pona) can handle well. Not sure how excited the market would be, but it is a significant opportunity with GIST prevalence increasing considerably.

EGFRm is really competitive these days.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News